Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde’s contribution to urothelial dysfunction in vitro

[1]  R. Chess-Williams,et al.  Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium , 2018, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  Yung-Hyun Choi,et al.  Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: the involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway. , 2014, International journal of oncology.

[3]  B. Davis,et al.  TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis , 2014, PAIN®.

[4]  K. Mansfield,et al.  Effect of Inflammatory Mediators on ATP Release of Human Urothelial RT4 Cells , 2014, BioMed research international.

[5]  Christian Gratzke,et al.  Pharmacology of the lower urinary tract , 2014, Indian journal of urology : IJU : journal of the Urological Society of India.

[6]  S. Mildenberger,et al.  The Nephrotoxic Ifosfamide-Metabolite Chloroacetaldehyde Interferes with Renal Extracellular Matrix Homeostasis , 2014, Cellular Physiology and Biochemistry.

[7]  Alexander V. Zhdanov,et al.  The mouse cyclophosphamide model of bladder pain syndrome: tissue characterization, immune profiling, and relationship to metabotropic glutamate receptors , 2014, Physiological reports.

[8]  P. O'Brien,et al.  Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. , 2013, Chemico-biological interactions.

[9]  R. Chess-Williams,et al.  Induction of inflammatory cytokines and alteration of urothelial ATP, acetylcholine and prostaglandin E2 release by doxorubicin. , 2013, European journal of pharmacology.

[10]  C. McClain,et al.  Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress. , 2012, Toxicology and applied pharmacology.

[11]  R. Vesela,et al.  Adenosine receptor antagonism suppresses functional and histological inflammatory changes in the rat urinary bladder , 2012, Autonomic Neuroscience.

[12]  J. Koropatnick,et al.  The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. , 2012, Anticancer research.

[13]  R. Chess-Williams,et al.  Effects of Pseudomonas aeruginosa virulence factor pyocyanin on human urothelial cell function and viability. , 2012, The Journal of urology.

[14]  N. Oyama,et al.  Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction. , 2011, The Journal of urology.

[15]  R. Ribeiro,et al.  Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder , 2011, Cancer Chemotherapy and Pharmacology.

[16]  G. Burnstock.  Therapeutic potential of purinergic signalling for diseases of the urinary tract , 2011, BJU international.

[17]  R. Chess-Williams,et al.  The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. , 2010, European urology.

[18]  R. Chess-Williams,et al.  In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic. , 2010, European urology.

[19]  A. Kanai,et al.  Is the urothelium intelligent? , 2010, Neurourology and urodynamics.

[20]  L. Birder,et al.  Urothelial signaling , 2010, Autonomic Neuroscience.

[21]  E. Burcher,et al.  Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch , 2009, British journal of pharmacology.

[22]  A. Ozkul,et al.  Effects of vitamin C and N-acetylcysteine against cyclophosphamide-induced genotoxicity in exfoliated bladder cells of mice in vivo. , 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[23]  G. Burnstock.  Purinergic mechanosensory transduction and visceral pain , 2009, Molecular pain.

[24]  J. de Vente,et al.  The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall , 2008, Journal of cellular and molecular medicine.

[25]  L. Birder,et al.  New insights into the pharmacology of the bladder , 2008, Current opinion in urology.

[26]  F. Schmitt,et al.  Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[27]  G. Koren,et al.  N‐Acetylcysteine prevents ifosfamide‐induced nephrotoxicity in rats , 2008, British journal of pharmacology.

[28]  D. Nicol,et al.  Urological implications of cyclophosphamide and ifosfamide , 2008, Scandinavian journal of urology and nephrology.

[29]  R. Chess-Williams,et al.  Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation. , 2007, The Journal of urology.

[30]  J. Wyndaele,et al.  Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. , 2007, European urology.

[31]  J. de Vente,et al.  The effects of exogenous prostaglandins and the identification of constitutive cyclooxygenase I and II immunoreactivity in the normal guinea pig bladder , 2007, BJU international.

[32]  G. Koren,et al.  The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. , 2007, Translational research : the journal of laboratory and clinical medicine.

[33]  Mary Beth Klinger,et al.  Expression of cyclooxygenase-2 in urinary bladder in rats with cyclophosphamide-induced cystitis. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  D. Averill-Bates,et al.  Inhibition of Acrolein-Induced Apoptosis by the Antioxidant N-Acetylcysteine , 2007, Journal of Pharmacology and Experimental Therapeutics.

[35]  A. Korkmaz,et al.  Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation , 2007, Cell Biology and Toxicology.

[36]  B. Luhovyy,et al.  Ifosfamide‐induced nephrotoxicity : Mechanism and prevention , 2006, Cancer research.

[37]  S. Murakami,et al.  Non-neuronal cholinergic system in human bladder urothelium. , 2006, Urology.

[38]  F. V. van Pelt,et al.  Resazurin assay of radiation response in cultured cells. , 2005, The British journal of radiology.

[39]  N. Sakura,et al.  Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[40]  J. Roppolo,et al.  Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. , 2003, American journal of physiology. Renal physiology.

[41]  G. Salvioli,et al.  Urinary and Plasma Homocysteine and Cysteine Levels during Prolonged Oral N-Acetylcysteine Therapy , 2003, Pharmacology.

[42]  G. Burnstock,et al.  Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder , 2002, The Journal of physiology.

[43]  S. Biswal,et al.  Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. , 2002, Chemical research in toxicology.

[44]  S. Biswal,et al.  The molecular effects of acrolein. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  R. Perez,et al.  Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  R. Chess-Williams,et al.  Urothelium‐derived inhibitory factor(s) influences on detrusor muscle contractility in vitro , 2000, British journal of pharmacology.

[47]  S. Biswal,et al.  Acrolein Causes Inhibitor κB-independent Decreases in Nuclear Factor κB Activation in Human Lung Adenocarcinoma (A549) Cells* , 1999, The Journal of Biological Chemistry.

[48]  A. El‐Yazigi,et al.  Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients , 1998, Bone Marrow Transplantation.

[49]  R. Martino,et al.  A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. , 1997, Cellular and molecular biology.

[50]  P. O'Brien,et al.  Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. , 1993, Biochemical pharmacology.

[51]  C. Pratt,et al.  DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY , 1986, The Lancet.

[52]  Lond Mb.  Frederick Ronald Chistopher Casson. , 1975 .

[53]  S. Eisman,et al.  Clinical evaluation of a new alkylating agent: Cytoxan (cyclophosphamide) , 1960, Cancer.

[54]  L. Birder,et al.  Urothelial signaling. , 2013, Physiological reviews.

[55]  H. Akino,et al.  Modulation of stretch evoked adenosine triphosphate release from bladder epithelium by prostaglandin E₂. , 2011, The Journal of urology.

[56]  K. Bielefeldt,et al.  Cyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons. , 2008, Journal of neurophysiology.

[57]  M. Gekle,et al.  Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells , 2005, Pediatric Nephrology.

[58]  M. Fukuoka,et al.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders , 2005, Journal of Cancer Research and Clinical Oncology.

[59]  W. C. Groat,et al.  Pharmacology of the lower urinary tract. , 2001, Annual review of pharmacology and toxicology.

[60]  S. Biswal,et al.  Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells. , 1999, The Journal of biological chemistry.

[61]  Sladek Ne.  Metabolism of oxazaphosphorines , 1988 .

[62]  K. Morgan,et al.  A critical review of the literature on acrolein toxicity. , 1985, Critical reviews in toxicology.

[63]  N. Brock,et al.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. , 1979, Arzneimittel-Forschung.